Tel.: 514-340-7593
antonios.douros@mcgill.ca
 
Antonios Douros
 
Investigator, Lady Davis Institute
Assistant Professor, Department of Medicine, McGill University
 
 
Dr. Antonios Douros is an Assistant Professor in the Department of Medicine, McGill University. He received his MD in 2009 and his Dr. med. (Doctorate Degree) in 2012, and was trained in Clinical Pharmacology from 2012 to 2016 at Charité – Universitätsmedizin Berlin in Berlin, Germany. After being awarded a research fellowship from the German Research Foundation, he completed a post-doctoral fellowship in pharmacoepidemiology from 2016 to 2018 at the Department of Epidemiology, Biostatistics and Occupational Health, McGill University. He then joined the Department of Medicine as an Assistant Professor in 2019.
 
Major Research Activities
 
During his post-doctoral fellowship, Dr. Douros investigated the safety of direct oral anticoagulants, drugs commonly used for stroke prevention in patients with atrial fibrillation, as well as the effectiveness and safety of antidiabetic drugs such as sulfonylureas, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide-1 receptor agonists. In these studies, he used the electronic healthcare databases of Québec and the United Kingdom Clinical Practice Research Datalink as data sources.

As an Assistant Professor, Dr. Douros will launch a research program in the effectiveness and safety of commonly prescribed medications in vulnerable populations, including patients with chronic kidney or liver disease, older adults, as well as patients affected by polypharmacy and potentially drug-drug interactions. Given the underrepresentation of such populations in randomized controlled trials, this research program will provide much needed information regarding the benefit-risk profile of drugs. For the implementation of this program, Dr. Douros will use his experience with large observational studies as well as his knowledge with respect to the distinct pharmacologic features of vulnerable populations.


Recent Publications
 
Douros A, Tölle M, Ebert N, Gaedeke J, Huscher D, Kreutz R, Kuhlmann MK, Martus P, Mielke N, Schneider A, Schuchardt M, van der Giet M, Schaeffner E. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study. Eur Heart J. 2019 Feb 25 [Epub ahead of print].

Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L. Glucagon-like peptide-1 receptor agonists and the risk of diabetic retinopathy. Diabetes Care. 2018;41(11):2330-2338.

Douros A, Dell'Aniello S, Yu OH, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018;362:k2693.

Douros A, Azoulay L, Yin H, Suissa S, Renoux C. Non-vitamin K antagonist oral anticoagulants and risk of serious liver injury. J Am Coll Cardiol. 2018;71(10):1105-1113.
Snapshot

Dr. Douros studies the effectiveness and safety of commonly prescribed medications in vulnerable populations.

 
 
Important Links


Support research at the Lady Davis Institute - Jewish General Hospital